Significant rise in number of registered patents, but majority of income from pharmaceuticals

Income from Israeli intellectual property in 2012-2013 totaled NIS 1,881 million but gap still exists between academic achievements and economic application.

By
August 26, 2014 21:19
1 minute read.
Pills

Pills. (photo credit: INGIMAGE / ASAP)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The number of patents registered by Israeli research institutions rose by an impressive 20 percent in 2012-2013 compared to the previous two years, the Science, Technology and Space Ministry disclosed on Tuesday.

The field with the most innovations was prescription drugs.

A survey by the ministry’s National Council for Research and Development found that 1,438 patents were registered – 1,000 of them completely new (not registered before in other countries).

The innovations led to the founding of 72 start-up companies here in the past two years.

The patents were registered by university research and development companies, hospitals and state-owned research institutes.

The university R&D companies specialized mostly in biotechnology, pharmaceuticals, physics, electronics, electrophysics, chemistry and nanotechnology. In the hospitals, the innovations were mainly in medical technology, while in the government research institutes they were in agriculture and plant genetics.

In 2012 and 2013, 967 applications for new patents were made.


Although the national council welcomed the increase in registered patents, “there still is a major gap between the many academic achievements in Israeli research institutes and the economic and application potential of know-how, Science, Technology and Space Minister Yaakov Peri said. “We are working with a lot of energy to reduce the gaps and increase government investment in applied research.”

While intellectual property in medications is prominent when measured by revenue, national council chairman Prof. Yitzhak Ben-Yisrael said, it must be remembered that the high income from them is from a small number of successful drugs such as Copaxone [for multiple sclerosis] and Exelon for Alzheimer’s disease.

“If we don’t increase our investments to bring about more developments in additional critical fields, industry will suffer harm in the near future and merely stand in place,” he added.

Income from Israeli intellectual property in 2012- 2013 totaled NIS 1,881 million.

Israeli-invented drugs provided 97 percent of this income, compared to 3 percent from innovations in physics, electronics, mathematics and electrooptics.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

June 20, 2019
Eighteen fruitful years

By BENJY SINGER

Cookie Settings